Búsqueda Imágenes Maps Play YouTube Noticias Gmail Drive Más »
Iniciar sesión
Usuarios de lectores de pantalla: deben hacer clic en este enlace para utilizar el modo de accesibilidad. Este modo tiene las mismas funciones esenciales pero funciona mejor con el lector.

Patentes

  1. Búsqueda avanzada de patentes
Número de publicaciónUS20040204705 A1
Tipo de publicaciónSolicitud
Número de solicitudUS 10/411,601
Fecha de publicación14 Oct 2004
Fecha de presentación10 Abr 2003
Fecha de prioridad10 Abr 2003
También publicado comoCA2521714A1, EP1610702A1, EP1610702B1, US8048066, US8585689, US9033967, US9339322, US9750556, US20090299358, US20120022513, US20140066914, US20150238244, US20160228174, WO2004091416A1
Número de publicación10411601, 411601, US 2004/0204705 A1, US 2004/204705 A1, US 20040204705 A1, US 20040204705A1, US 2004204705 A1, US 2004204705A1, US-A1-20040204705, US-A1-2004204705, US2004/0204705A1, US2004/204705A1, US20040204705 A1, US20040204705A1, US2004204705 A1, US2004204705A1
InventoresDaniel Lafontaine
Cesionario originalScimed Life Systems, Inc.
Exportar citaBiBTeX, EndNote, RefMan
Enlaces externos: USPTO, Cesión de USPTO, Espacenet
Cryotreatment devices and methods of forming conduction blocks
US 20040204705 A1
Resumen
Cryotreatment devices and methods of ablating tissue within the body are disclosed. A cryotreatment device in accordance with an exemplary embodiment of the present invention includes an elongated member having one or more needle-like ablation tips configured to induce necrosis at a target site within the heart. A cooling fluid such as a cryogen may be injected through a lumen extending into the distal portion of the device. The ablation tips can be configured to pierce and ablate surrounding tissue, blocking electrical stimuli that can cause fibrillations or other arrhythmias of the heart. The device may also include means for controlling the transmural depth at which the ablation tips are inserted into the cardiac tissue. Methods of forming a contiguous line of conduction block in accordance with the present invention are also disclosed.
Imágenes(5)
Previous page
Next page
Reclamaciones(44)
What is claimed is:
1. A medical device for inducing controlled necrosis at a target site within the body, comprising:
an elongated member having a proximal portion, a distal portion, and at least one lumen therein in fluid communication with a cooling fluid;
at least one ablation tip coupled to the distal portion of said elongated member configured to contact and ablate tissue; and
means for controlling the transmural depth of said at least one ablation tip into the tissue.
2. The medical device of claim 1, wherein said elongated member includes an inner shaft defining an intake lumen for said cooling fluid, and an outer shaft defining an exhaust lumen for said cooling fluid.
3. The medical device of claim 2, wherein said inner shaft includes at least one aperture configured to eject cooling fluid from said intake lumen into said exhaust lumen.
4. The medical device of claim 3, wherein said at least one aperture comprises a throttling element.
5. The medical device of claim 1, wherein said cooling fluid is a cryogen.
6. The medical device of claim 5, wherein said cryogen is liquid nitrous oxide.
7. The medical device of claim 5, wherein said cryogen is selected from the group consisting of liquid nitrogen, carbon dioxide, chlorodifluoromethane, polydimethysiloxane, ethyl alcohol, and chlorofluorocarbons.
8. The medical device of claim 1, wherein said means for controlling the transmural depth of said at least one ablation tip comprises an ultrasonic probe.
9. The medical device of claim 1, wherein said means for controlling the transmural depth of said at least one ablation tip comprises a control wire.
10. The medical device of claim 1, wherein said at least one ablation tip is a needle-like ablation tip.
11. The medical device of claim 1, wherein said at least one ablation tip comprises a plurality of ablation tips.
12. The medical device of claim 11, wherein said plurality of ablation tips is retractable within the distal portion of said elongated member.
13. The medical device of claim 11, wherein said plurality of ablation tips is linearly arranged along the distal portion of said elongated member.
14. The medical device of claim 11, wherein said plurality of ablation tips is radially arranged about the distal portion of said elongated member.
15. The medical device of claim 11, wherein said plurality of ablation tips is configured to form a line of conduction block at said target site.
16. The medical device of claim 1, wherein the distal portion of said elongated member is radially enlarged.
17. The medical device of claim 1, further comprising a guiding member configured to transport said elongated member to the target site.
18. A medical device for inducing controlled necrosis at a target site within the body, comprising:
an elongated member having a proximal portion, a distal portion, and at least one lumen therein in fluid communication with a cooling fluid;
a plurality of ablation tips coupled to the distal portion of said elongated member configured to contact and ablate tissue, said plurality of ablation tips configured to form a line of conduction block at said target site; and
means for controlling the transmural depth of said plurality of ablation tips into the tissue.
19. The medical device of claim 18, wherein said elongated member includes an inner shaft defining an intake lumen for said cooling fluid, and an outer shaft defining an exhaust lumen for said cooling fluid.
20. The medical device of claim 19, wherein said inner shaft includes at least one aperture configured to eject cooling fluid from said intake lumen into said exhaust lumen.
21. The medical device of claim 20, wherein said at least one aperture comprises a throttling element.
22. The medical device of claim 18, wherein said cooling fluid is a cryogen.
23. The medical device of claim 22, wherein said cryogen is liquid nitrous oxide.
24. The medical device of claim 22, wherein said cryogen is selected from the group consisting of liquid nitrogen, carbon dioxide, chlorodifluoromethane, polydimethysiloxane, ethyl alcohol, and chlorofluorocarbons.
25. The medical device of claim 18, wherein said means for controlling the transmural depth of said plurality of ablation tips comprises an ultrasonic probe.
26. The medical device of claim 18, wherein said means for controlling the transmural depth of said at least one ablation tip comprises a control wire.
27. The medical device of claim 18, wherein each of said plurality of ablation tips are needle-like ablation tips.
28. The medical device of claim 18, wherein each said plurality of ablation tips are retractable within the distal portion of said elongated member.
29. The medical device of claim 18, wherein said plurality of ablation tips is linearly arranged along the distal portion of said elongated member.
30. The medical device of claim 18, wherein said plurality of ablation tips is radially arranged about the distal portion of said elongated member.
31. The medical device of claim 18, wherein the distal portion of said elongated member is radially enlarged.
32. The medical device of claim 18, further comprising a guiding member configured to transport said elongated member to the target site.
33. A medical device for inducing controlled necrosis at a target site within the body, comprising:
an elongated member having a proximal portion, a distal portion, and at least one lumen therein in fluid communication with a cooling fluid;
at least one retractable ablation tip coupled to the distal portion of said elongated member, said at least one retractable ablation tip being configured to contact and ablate tissue; and
at least one control wire configured to retract said at least one retractable ablation tip within said tissue.
34. A cryosurgical method for inducing controlled necrosis at a target site within the heart, comprising the steps of:
providing a cryotreatment device having a proximal portion, a distal portion, and at least one lumen therein in fluid communication with a cryogenic fluid, the distal portion of said cryotreatment device including at least one ablation tip configured to contact and ablate tissue;
advancing the cryotreatment device to the target site and inserting said at least one ablation tip into the tissue;
controlling the transmural depth of said at least one ablation tip into the tissue; and
injecting the cryogenic fluid through said at least one lumen to the distal portion of the cryotreatment device.
35. The method of claim 34, wherein the step of controlling the transmural depth of said at least one ablation tip into the tissue comprises the steps of:
providing an ultrasonic probe at or near the target site proximal said at least one ablation tip; and
acoustically measuring the penetration depth of said at least one ablation tip into the tissue.
36. The method of claim 34, wherein the steps of creating transmural necrosis are accomplished by inserting one ablation tip into the tissue to a controlled depth and anchoring by freezing to the tissue then connectively placing the next.
37. The method of claim 34, wherein said at least one ablation tip comprises a plurality of ablation tips configured to form a line of conduction block at the target site.
38. The method of claim 34, wherein the step of injecting the cryogenic fluid through said at least one lumen to the distal portion of the cryotreatment device comprises the steps of:
supplying cryogenic fluid through an intake lumen to the distal portion of the cryotreatment device; and
ejecting the cryogenic fluid through one or more apertures into an exhaust lumen, said one or more apertures configured to cool the cryogenic fluid.
39. A cryosurgical method for inducing controlled necrosis at a target site within the heart, comprising the steps of:
providing a cryotreatment device having a proximal portion, a distal portion, and at least one lumen therein in fluid communication with a cryogenic fluid, the distal portion of said cryotreatment device including a plurality of linearly-disposed ablation tips configured to contact and ablate tissue;
advancing the cryotreatment device to the target site;
inserting said plurality of ablation tips into the tissue;
controlling the transmural depth of said plurality of ablation tips into the tissue; and
injecting the cryogenic fluid through said at least one lumen to the distal portion of the cryotreatment device to form a line of conduction block at the target site.
40. The method of claim 39, wherein the step of controlling the transmural depth of said plurality of ablation tips into the tissue comprises the steps of:
providing an ultrasonic probe at or near the target site proximal said plurality of ablation tips; and
acoustically measuring the penetration depth of said plurality of ablation tips into the tissue.
41. The method of claim 39, wherein the step of injecting the cryogenic fluid through said at least one lumen to the distal portion of the cryotreatment device comprises the steps of:
supplying cryogenic fluid through an intake lumen to the distal portion of the cryotreatment device; and
ejecting the cryogenic fluid through one or more apertures into an exhaust lumen, said one or more apertures configured to cool the cryogenic fluid.
42. A cryosurgical method for inducing controlled necrosis at a target site within the heart, comprising the steps of:
providing a cryotreatment device having a proximal portion, a distal portion, and at least one lumen therein in fluid communication with a cryogenic fluid, the distal portion of said cryotreatment device including a plurality of radially-disposed ablation tips configured to contact and ablate tissue;
advancing the cryotreatment device to the target site;
inserting said plurality of ablation tips into the tissue;
controlling the transmural depth of said plurality of ablation tips into the tissue; and
injecting the cryogenic fluid through said at least one lumen to the distal portion of the cryotreatment device to form a circumferential line of conduction block at the target site.
43. A cryosurgical method for inducing controlled necrosis at a target site within the heart, comprising the steps of:
providing a cryotreatment device having a proximal portion, a distal portion, and at least one lumen therein in fluid communication with a cryogenic fluid, the distal portion of said cryotreatment device including a plurality of ablation tips configured to contact and ablate tissue;
advancing the cryotreatment device along a guiding member to the target site and inserting said plurality of ablation tips into the tissue;
providing an ultrasonic probe at or near the target site proximal said plurality of ablation tips and acoustically measuring the penetration depth of said plurality of ablation tips into the tissue; and
injecting the cryogenic fluid through said at least one lumen to the distal portion of the cryotreatment device, thereby forming a conduction block within the target site blocking electrical signals to one or more relay points within the heart.
44. The method of claim 43, wherein said guiding member comprises a guide catheter disposed along a guidewire.
Descripción
    FIELD OF THE INVENTION
  • [0001]
    The present invention relates generally to medical devices for ablating tissue at one or more target sites. More specifically, the present invention relates to cryotreatment devices and methods for inducing controlled necrosis of cardiac tissue within the heart.
  • BACKGROUND OF THE INVENTION
  • [0002]
    Cardiac arrhythmias such as atrial fibrillation, bradycardia, ventricular tachycardia, ventricle fibrillation, and Wolff-Parkinson-White syndrome are common heart abnormalities that cause stroke, myocardial infarction, and other thromboembolic events within the body. In patients with normal sinus rhythm, the heart is electrically excited to beat in a synchronous and patterned manner, typically at a rate of 60 to 100 beats per minute (bpm). In contrast, in patients with cardiac arrhythmia, abnormal regions of the cardiac tissue may aberrantly conduct to adjacent tissue, causing the heart to beat irregularly. In ventricular tachycardia, for example, electrical signals may be errantly received in the lower heart chamber (i.e. the ventricle) instead of the right, upper chamber (i.e. the atria), causing the heart to beat rapidly. In atrial fibrillation, the most common type of cardiac arrhythmia, the upper chambers of the heart beat at an uncontrolled rate of 350 to 600 bpm, which results in a reduction of the pumping force of the heart. As a result of this reduced pumping force, blood in the heart chambers may become stagnant and pool, forming blood clots that can dislodge within the body and cause stroke or other life threatening events.
  • [0003]
    To treat cardiac arrhythmia, a number of therapeutic procedures have been developed, including RF catheter ablation, chemical cardioversion, percutaneous myocardial revascularization (PMR), and suppression. Antiarrhythmic medications such as beta-blockers, calcium channel blockers, anticoagulants, and DIGOXIN have also been used successfully to treat some forms of cardiac arrhythmia. More recent trends have focused on the use of cryotreatment catheters to treat arrhythmias such as atrial fibrillation and ventricular tachycardia. Such devices provide a relatively non-invasive method of treatment in comparison to other surgical techniques.
  • [0004]
    In one such method, for example, a catheter loaded with a cryogenic cooling fluid may used to cryogenically cool cardiac tissue at strategic locations of the heart, such as the right and left atria, or the pulmonary veins. The catheter can be used to induce necrosis at one or more pre-mapped target sites within the heart to create conduction blocks within the aberrant electrical conduction pathways. In atrial fibrillation, for example, necrosis of one or more target sites within the atrial cardiac muscle tissue can be used to block the electrical signals believed to cause and/or sustain the fibrillation.
  • [0005]
    In some techniques, the use of a cryotreatment device to form the required conduction block may be ineffective since there is no adequate means to control the transmural depth of the lesion, or the distance between each lesion. To compensate for these shortcomings, many cryotreatment devices utilize relatively large catheter tips, which destroy more tissue than is necessary to form the conduction block and further reduce the already weakened pumping force of the heart. It is therefore desirable to have a cryotreatment device capable of transmurally controlling the depth of each lesion and in a contiguous manner.
  • SUMMARY OF THE INVENTION
  • [0006]
    The present invention relates generally to cryotreatment devices and methods for reducing or eliminating arrhythmia by inducing controlled necrosis at one or more pre-mapped target sites within the heart. A cryotreatment device in accordance with an exemplary embodiment of the present invention may comprise an elongated member having a proximal portion, a distal portion, and one or more lumens therein in fluid communication with a cooling fluid adapted to cool the distal portion of the elongated member. The elongated member may include one or more needle-like ablation tips configured to pierce and necrotize cardiac tissue within the heart, preventing the conduction of aberrant electrical signals through the tissue to one or more relay sites of arrthymogenic foci. The cryotreatment device may include one or more features configured to form an array of ablations within the cardiac tissue, forming a contiguous line of conduction block.
  • [0007]
    The ablation tips may be retractable within the elongated member to control the penetration depth of the tips transmurally into the cardiac tissue. A pull cord operatively coupled to the ablation tip can be used to retract the ablation tip from the cardiac tissue. An ultrasonic probe or other measuring device may also be provided to measure and control the insertion depth of the cryotreatment device within the cardiac tissue.
  • [0008]
    A cryosurgical method in accordance with the present invention may comprise the steps of providing a cryotreatment device to a target site within the heart, and necrotizing one or more locations within the cardiac tissue to form a contiguous line of conduction block. A cooling fluid such as liquid nitrous oxide can be injected through an inner lumen extending to the distal portion of the cryotreatment device to cool the surrounding tissue adjacent the ablation tips.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0009]
    [0009]FIG. 1 is an illustration of a cryotreatment device in accordance with an exemplary embodiment of the present invention, wherein the device is shown inserted through the septal wall of the heart and advanced to a target site at or near one or more relay points;
  • [0010]
    [0010]FIG. 2 is a partial cross-sectional view of the cryotreatment device of FIG. 1;
  • [0011]
    [0011]FIG. 3 is a detailed view of the cryotreatment device of FIGS. 1-2, wherein the device includes an ultrasonic probe adapted measure and control the transmural depth of the device into the cardiac tissue;
  • [0012]
    [0012]FIG. 4 is another detailed view illustrating multiple cryotreatment devices coupled together using a coupling member;
  • [0013]
    [0013]FIG. 5 is a view of a cryotreatment device in accordance with an exemplary embodiment of the present invention, wherein the cryotreatment device includes a linear array of ablation tips;
  • [0014]
    [0014]FIG. 6 is a partial cross-sectional view of a cryotreatment device in accordance with an exemplary embodiment of the present invention, wherein the cryotreatment device includes several retractable cryogenic tips configured to form a circumferential line of conduction block within the heart; and
  • [0015]
    [0015]FIG. 7 is a partial cross-sectional view of a cryotreatment device in accordance with another exemplary embodiment of the present invention, wherein the cryotreatment devices includes an enlarged distal portion with retractable ablation tips.
  • DETAILED DESCRIPTION OF THE INVENTION
  • [0016]
    The following description should be read with reference to the drawings, in which like elements in different drawings are numbered in like fashion. The drawings, which are not necessarily to scale, depict selected embodiments and are not intended to limit the scope of the invention. Although examples of construction, dimensions, and materials are illustrated for the various elements, those skilled in the art will recognize that many of the examples provided have suitable alternatives that may be utilized.
  • [0017]
    [0017]FIG. 1 is an illustrative view of a cryotreatment device 10 in accordance with an exemplary embodiment of the present invention for inducing controlled necrosis at one or more pre-mapped target sites within the heart. A guide wire 12 inserted percutaneously into the femoral or jugular veins is shown advanced through the septal wall 14 and into the upper chambers 16,18 of a heart 20. Using known manipulation techniques in the art, guidewire 12 can be advanced to a location distal a target site 22 determined to cause electrical interference with one or more downstream arrythmogenic foci 24. A guide catheter 26 sufficiently sized to receive cryotreatment device 10 can be used to advance the cryotreatment device 10 to a location at or near the target site 22.
  • [0018]
    Arrhythmias such as atrial flutter, atrial fibrillation and ventricular tachycardia are typically caused when abnormal regions of the heart transmit aberrant electrical signals vis-à-vis arrythmogenic foci. To treat such arrhythmias, a cryotreatment device in accordance with the present invention can be inserted into cardiac tissue at a pre-mapped target site and cooled to a temperature of about −40 to −100° C. to induce necrosis at one or more locations 28,30,32,34 within the heart, such as the pulmonary vein 36. The cryotreatment device can be inserted at the various locations 28,30,32,34 to form a line of conduction block that prevents certain electrical signals from being sent from the foci points 24. In necrotizing the cardiac tissue at several locations, thereby forming a line of conduction block in the pulmonary vein 36, the transmission of aberrant signals believed to cause the arrhythmia can be reduced or in some cases altogether eliminated.
  • [0019]
    [0019]FIG. 2 is a partial cross-sectional view of the cryotreatment device 10 of FIG. 1, showing the distal portion 38 of the device 10 in greater detail. In the exemplary embodiment of FIGS. 1-2, cryotreatment device 10 comprises a multiple lumen catheter body 40 having an outer shaft 42 configured to pierce and cool the cardiac tissue, and an inner shaft 44 defining an inner lumen 46 in fluid communication with a cooling fluid. The outer shaft 42 of catheter body 40 may have a transverse cross-sectional area that is substantially circular in shape, extending from a proximal end (not shown) located outside of the patient's body to a transition region 48 on the catheter body 40. At transition region 48, catheter body 40 tapers distally to a needle-like ablation tip 50 configured to pierce and contact cardiac tissue.
  • [0020]
    To cool the distal portion 38 of cryotreatment device 10 to a sufficiently low temperature to induce necrosis when inserted into cardiac tissue, cryotreatment device 10 can be placed in fluid communication with a cooling fluid such as liquid nitrogen, nitrous oxide (N2O), carbon dioxide (C2O), chlorodifluoromethane, polydimethysiloxane, ethyl alcohol, chlorofluorocarbons (Freon), or other suitable fluid. The cooling fluid can be delivered in either a liquid or gas state through inner lumen 46, and injected into the annular space 52 between the outer and inner shafts 42,44 through several apertures 54 disposed in the inner shaft 44. In one embodiment, for example, pressurized liquid nitrous oxide can be fluidly coupled to the inner lumen 46 of catheter body 40, and ejected through several apertures 54 disposed in the inner lumen 44. Using the Joule-Thompson cooling effect, the apertures 54 are adapted to act as a throttling element (e.g. a throttling nozzle) for the cryogen, producing isenthalpic cooling as the fluid is expended from a relatively high pressure within the inner lumen 46 to a lower pressure as it enters the annular space 52. As the cryogenic fluid expands as it passes through the apertures 54, it transitions to a gas and impinges upon the interior wall 56 of the outer shaft 42 cooling the distal portion 38 of the catheter body 40. This temperature drop is then thermally transferred through the catheter body 40 and into the surrounding cardiac tissue 58, inducing necrosis at the target site 22. The cryogenic fluid is subsequently returned through annular lumen 52 to the proximal end of the device 10.
  • [0021]
    The number of apertures 54 can be varied to provide a desired temperature decrease to the distal portion 38 of the catheter body 40. The type of cryogen used and the pressure and/or volume at which the cryogen is delivered through the inner lumen 46 can also be selected to impart a particular cooling characteristic to the device 10, as desired. In the exemplary embodiment of FIGS. 1-2, cryotreatment device 10 includes several equidistantly spaced apertures 54 configured to provide uniform cooling through the distal portion 38 of the catheter body 40. It should be recognized, however, that the apertures 54 could be placed at any number of strategic locations, at either equidistant or non-equidistant intervals, to direct the cryogenic fluid to a particular location within the device 10.
  • [0022]
    The outer and inner shafts 42,44 of cryotreatment device 10 may be fabricated from materials having certain desirable flexibility and thermodynamic properties. For example, the outer and inner shafts 42,44 may each be formed of a superelastic material such as nickel-titanium alloy (Nitinol) to permit the cryotreatment device 10 to be inserted through relatively tortuous locations of the body without kinking. Other suitable biocompatible materials such stainless steel or a polymer/metal composition may also be utilized, depending on the particular application.
  • [0023]
    Referring now to FIG. 3, methods of using cryotreatment device 10 will now be described in the context of a cryosurgical procedure to necrotize cardiac tissue 58 within a body lumen such as a pulmonary vein 36. Cryotreatment device 10 can be inserted through a previously positioned guide catheter 26 and advanced to a pre-mapped target site 22 within the heart believed to transmit aberrant electrical signals to one or more relay points. As shown in FIG. 3, needle-like ablation tip 50 of device 10 can be configured to pierce and contact the cardiac tissue 58 of pulmonary vein 36, allowing the distal portion 38 of catheter body 40 to be inserted into the cardiac tissue 58. A curved portion 60 on the catheter body 40 may be adapted to orient the needle-like ablation tip 50 in a direction substantially perpendicular to the tissue wall 58.
  • [0024]
    In one aspect of the present invention, cryotreatment device 10 can be configured to measure and control the transmural depth at which the device is inserted into the cardiac tissue 58. Controlled insertion of the needle-tip ablation tip 50 into the cardiac tissue 58 prevents distension of the vein 36 from occurring, and prevents the ablation of cardiac tissue not necessary to form the conduction block. Controlled insertion of the needle-like ablation tip 50 into the cardiac tissue 58 also ensures that the cryotreatment device 10 is inserted at a sufficient depth to form the desired conduction block.
  • [0025]
    An ultrasonic probe 62 or other measurement device may be utilized to measure the precise depth at which cryotreatment device 10 is inserted into the cardiac tissue 58. The ultrasonic probe 62 can be coupled to catheter body 40 a predetermined distance from the needle-like ablation tip 50, and engaged to acoustically measure the depth at which the distal portion 38 is inserted into the cardiac tissue 58. The ultrasonic probe 62 may be coupled to the catheter body 40, or may be formed as a separate element that can be advanced along the catheter body 40 and positioned proximal the cardiac tissue 58. In one exemplary embodiment, the ultrasonic probe 62 may act as a guiding member for the device 10, eliminating the need for a separate guide catheter. Those of skill in the art will readily recognize that other suitable devices for measuring the insertion depth of the cryotreatment device 10 may be employed, including, for example, the use of an optical probe, acoustic reflective coatings, distal bipolar electrodes, or through the use radiographic techniques such as fluoroscopic marker bands.
  • [0026]
    In operation, a fluid controller or other similar device can be coupled to the proximal end of the cryotreatment device 10 and used to inject a controlled flow of cryogenic fluid (e.g. liquid N2O) through the inner lumen 46. One or more temperature sensors (not shown) on the distal portion 38 of catheter body 40 may also optionally be used to monitor the temperature of the device 10 and adjust the flow rate via the fluid controller, as necessary. An insulated sleeve 64 surrounding the catheter body 40 may be utilized to thermally isolate the catheter body 40 proximal the distal portion 38 to prevent ablating other areas of the body.
  • [0027]
    In certain embodiments, the cryotreatment device may include a coupling member configured to couple multiple ablation tips together in an array. As shown in FIG. 4, for example, a coupling member 66 can be used to connect multiple cryotreatment devices 10 together, forming a linear array of needle-like ablation tips 50 that, when thermally cooled via a cryogenic fluid, create a line of contiguous conduction block along the cardiac tissue 58 at the target site 22. The coupling member 66 can be configured to couple together any number of cryotreatment devices together in any desired array or pattern. The multiple cooling members 10 applied in a sequential cooling method will allow the lesions to be made in a stitched like fashion to ensure contiguous connection of all the lesions. The method of stitching is accomplished by moving one needle 50 while the other needle 50′ is anchored and froze into the tissue. The sequence of operation would be as follows:
  • [0028]
    1. Insert two needles at start point and apply maximum freeze;
  • [0029]
    2. Thaw the proximal needle and reduce temperature on distal needle;
  • [0030]
    3. Retract proximal needle and rotate around anchored distal needle;
  • [0031]
    4. Apply maximum cooling on both needles and repeat steps 2-4.
  • [0032]
    [0032]FIG. 5 is a view of a cryotreatment device 68 in accordance with another exemplary embodiment of the present invention. Cryotreatment 68 comprises a catheter body 70 having several linearly disposed ablation tips 72 along a distal portion 74 that, when placed into fluid communication with a cryogenic cooling fluid, are configured to form a line of conduction block within a target site of the heart. Each ablation tip 72 may be configured similar to tip 50 described above, having a needle-like shape configured to pierce and contact the cardiac tissue when inserted. The number of needles 72 and lumens 76 may be the same as shown, or may be as few as two needles 72 for any number of lumens 76 in the method previously described. An inner lumen 76 in fluid communication with a source of pressurized cryogen at or near the proximal end of the device 70 is configured to cool each ablation tip 72 in a manner similar that described above with respect to cryotreatment device 10. The cryotreatment device 70 may also optionally include an ultrasonic probe or other measurement means (not shown) for measuring the precise depth at which the ablations tips 72 are transmurally inserted into the cardiac tissue. An insulation layer 78 surrounding the catheter body 70 thermally insulates the body 70 from ablating other areas of the body.
  • [0033]
    To form a line of conduction block within a target site of the heart, ablation tips 72 can be aligned with a portion of the cardiac tissue believed to transfer the aberrant electrical signal(s) to one or more downstream relay points, and inserted into the tissue at a controlled depth. A pressurized cryogenic fluid can be delivered through the catheter body 70, causing the ablation tips 72 on the distal portion 74 to undergo a temperature drop to a temperature of about −40 to −100° C., inducing necrosis in the surrounding cardiac tissue.
  • [0034]
    The destruction of more tissue than is necessary to form the conduction block may be mitigated through the use of a series of smaller ablation tips. Moreover, the number, shape and arrangement of the ablation tips may be varied in accordance with the particular application. In certain applications, for example, a cryotreatment device in accordance with the present invention may be configured to form a circumferential line of conduction blocks at a target site within the heart.
  • [0035]
    In one exemplary embodiment shown in FIG. 6, a cryotreatment device 80 in accordance with the present invention may include a catheter body 82 having several needle-like ablation tips 84 on distal end 86 that, when thermally cooled via a supplied source of cryogenic fluid, form a circumferential line of conduction block at a target site within the heart (e.g. about a pulmonary vein). Cryotreatment device 80 may comprise an outer shaft 88, and an inner shaft 90 disposed within the outer shaft 88. The inner shaft 90 can be configured to deliver a pressurized source of cryogenic fluid such as liquid nitrogen or N2O through aperture 92 towards the interior surface 94 of distal end 86, causing the interior surface 94 of the distal end 86 of catheter body 82 to cool and conduct heat.
  • [0036]
    Each of the needle-like ablation tips 84 can be configured to retract through several openings 96 disposed on the distal end 86 of the catheter body 82. A control wire 98 extending proximally from each ablation tip 84 to a location outside of the patient's body may be used to retract each tip 84 through its respective opening 96, allowing the operator to adjust the precise depth at which the tip 84 is inserted the cardiac tissue. A flange 100 coupled to each ablation tip 84 prevents the tip 84 from being pulled proximally through opening 96 as control wire 98 is retracted. As with any of the other embodiments described herein, an ultrasonic probe or other suitable device can be utilized to measure and, if necessary, control the penetration depth of the ablation tips 84 within the tissue.
  • [0037]
    In use, cryotreatment device 80 can be advanced to a target site within the heart, and, with the ablation tips 84 initially in a fully deployed position, inserted into the cardiac tissue. Once the device 80 is inserted into the tissue, the operator can retract the control wire 98 proximally a distance, causing the ablation tips 84 to retract from within the tissue a slight distance (e.g. 0.5-3.0 cm). An ultrasonic probe or other suitable device may be used to measure the precise depth at which the ablation tips 84 are inserted into the cardiac tissue. At the desired depth, a pressurized flow of cryogen is then delivered through the device, causing the distal end 86 of the device, including the ablation tips 84, to cool to a temperature of about −40 to −100° C., forming a circumferential line of conduction block within the body.
  • [0038]
    [0038]FIG. 7 is a partial cross-sectional view of a cryotreatment device 102 in accordance with another exemplary embodiment of the present invention. Cryotreatment device 102 comprises an outer shaft 104 having a proximal portion (not shown), a distal portion 106, and an inner lumen 108 in fluid communication with a cooling fluid such as liquid N2O. The distal portion 106 of cryotreatment device 102 may be enlarged slightly, orienting several retractable needle-like ablation tips 110 in a wider radial array, permitting the formation of a circumferential line of conduction block at larger target sites. A control wire 112 operatively coupled to each ablation tip 110 can be utilized to adjust the transmural depth of the tip 110 into the cardiac tissue. A flanged portion 114 on each ablation tip 110 prevents the operator from pulling the ablation tip 110 proximally through the tip openings 116 on the distal portion 106 of the outer shaft 104.
  • [0039]
    Having thus described the several embodiments of the present invention, those of skill in the art will readily appreciate that other embodiments may be made and used which fall within the scope of the claims attached hereto. Numerous advantages of the invention covered by this document have been set forth in the foregoing description. It will be understood that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of shape, size and arrangement of parts without exceeding the scope of the invention.
Citas de patentes
Patente citada Fecha de presentación Fecha de publicación Solicitante Título
US3298371 *11 Feb 196517 Ene 1967Arnold S J LeeFreezing probe for the treatment of tissue, especially in neurosurgery
US3782386 *8 May 19721 Ene 1974Dynatech CorpCryosurgical apparatus
US3913581 *1 Jun 197321 Oct 1975Spembly LtdCryogenic apparatus
US4015606 *9 Sep 19755 Abr 1977Dynatech CorporationMethod and means for controlling the freeze zone of a cryosurgical probe
US4207897 *13 Jul 197717 Jun 1980Spembly LimitedCryosurgical probe
US4924679 *2 Oct 198915 May 1990Zwick Energy Research Organization, Inc.Apparatus and method for evacuating an insulated cryogenic hose
US5078713 *30 Nov 19897 Ene 1992Spembly Medical LimitedCryosurgical probe
US5147355 *23 Sep 198815 Sep 1992Brigham And Womens HospitalCryoablation catheter and method of performing cryoablation
US5254116 *6 Sep 199119 Oct 1993Cryomedical Sciences, Inc.Cryosurgical instrument with vent holes and method using same
US5281213 *16 Abr 199225 Ene 1994Implemed, Inc.Catheter for ice mapping and ablation
US5281215 *15 Jun 199225 Ene 1994Implemed, Inc.Cryogenic catheter
US5334181 *31 Ene 19922 Ago 1994Cryomedical Sciences, Inc.Cryosurgical system for destroying tumors by freezing
US5403309 *29 Jul 19934 Abr 1995Spembly Medical LimitedCryosurgical ablation
US5403311 *29 Mar 19934 Abr 1995Boston Scientific CorporationElectro-coagulation and ablation and other electrotherapeutic treatments of body tissue
US5425582 *15 Ene 199320 Jun 1995Hochiki Kabushiki KaishaThermal detector and method of producing the same
US5501681 *12 Nov 199326 Mar 1996Neuwirth; Robert S.Intrauterine cryoablation cauterizing apparatus and method
US5624392 *8 Ago 199429 Abr 1997Saab; Mark A.Heat transfer catheters and methods of making and using same
US5688267 *1 May 199518 Nov 1997Ep Technologies, Inc.Systems and methods for sensing multiple temperature conditions during tissue ablation
US5716353 *3 May 199610 Feb 1998Urds, Corp.Cryosurgical instrument
US5733280 *15 Nov 199531 Mar 1998Avitall; BoazCryogenic epicardial mapping and ablation
US5741248 *7 Jun 199521 Abr 1998Temple University-Of The Commonwealth System Of Higher EducationFluorochemical liquid augmented cryosurgery
US5807391 *23 Sep 199615 Sep 1998Cordis CorporationCryo-ablation catheter
US5853368 *23 Dic 199629 Dic 1998Hewlett-Packard CompanyUltrasound imaging catheter having an independently-controllable treatment structure
US5885276 *2 Dic 199723 Mar 1999Galil Medical Ltd.Method and device for transmyocardial cryo revascularization
US5893848 *24 Oct 199613 Abr 1999Plc Medical Systems, Inc.Gauging system for monitoring channel depth in percutaneous endocardial revascularization
US5951546 *24 Nov 199514 Sep 1999Lorentzen; TorbenElectrosurgical instrument for tissue ablation, an apparatus, and a method for providing a lesion in damaged and diseased tissue from a mammal
US6074412 *29 Ago 199813 Jun 2000Endocare, Inc.Cryoprobe
US6164283 *29 Ene 199926 Dic 2000The Regents Of The University Of CaliforniaDevice and method for forming a circumferential conduction block in a pulmonary vein
US6355029 *1 Dic 199812 Mar 2002Cryovascular Systems, Inc.Apparatus and method for cryogenic inhibition of hyperplasia
US6451012 *5 Feb 200117 Sep 2002Cryogen, Inc.Cryosurgical method for endometrial ablation
US6506189 *21 Ago 200014 Ene 2003Sherwood Services AgCool-tip electrode thermosurgery system
US6527767 *20 May 19984 Mar 2003New England Medical CenterCardiac ablation system and method for treatment of cardiac arrhythmias and transmyocardial revascularization
US20020040220 *31 Jul 20014 Abr 2002Roni ZvuloniPlanning and facilitation systems and methods for cryosurgery
US20030029462 *14 Jun 200213 Feb 2003Epicor, Inc.Device and method for forming a lesion
Citada por
Patente citante Fecha de presentación Fecha de publicación Solicitante Título
US77132665 Dic 200511 May 2010Myoscience, Inc.Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US785068328 Jun 200714 Dic 2010Myoscience, Inc.Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US78625586 Mar 20094 Ene 2011Myoscience, Inc.Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US799813712 Abr 201016 Ago 2011Myoscience, Inc.Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US80078477 Ago 200630 Ago 2011Eytan BidermanFeeding formula appliance
US8066697 *18 Dic 200629 Nov 2011Galil Medical Ltd.Multiple cryoprobe delivery apparatus
US829821614 Nov 200830 Oct 2012Myoscience, Inc.Pain management using cryogenic remodeling
US840918516 Feb 20072 Abr 2013Myoscience, Inc.Replaceable and/or easily removable needle systems for dermal and transdermal cryogenic remodeling
US871527513 Sep 20126 May 2014Myoscience, Inc.Pain management using cryogenic remodeling
US901731822 Ene 201328 Abr 2015Myoscience, Inc.Cryogenic probe system and method
US906671222 Dic 200930 Jun 2015Myoscience, Inc.Integrated cryosurgical system with refrigerant and electrical power source
US907249817 Nov 20107 Jul 2015Myoscience, Inc.Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US910134630 Sep 201311 Ago 2015Myoscience, Inc.Pain management using cryogenic remodeling
US91138555 Mar 201325 Ago 2015Myoscience, Inc.Replaceable and/or easily removable needle systems for dermal and transdermal cryogenic remodeling
US915558414 Ene 201313 Oct 2015Myoscience, Inc.Cryogenic probe filtration system
US924175314 Ene 201326 Ene 2016Myoscience, Inc.Skin protection for subdermal cryogenic remodeling for cosmetic and other treatments
US925416221 Dic 20069 Feb 2016Myoscience, Inc.Dermal and transdermal cryogenic microprobe systems
US929551212 Sep 201329 Mar 2016Myoscience, Inc.Methods and devices for pain management
US9314290 *14 Ene 201319 Abr 2016Myoscience, Inc.Cryogenic needle with freeze zone regulation
US933932213 May 201517 May 2016Boston Scientific Scimed Inc.Cryotreatment devices and methods of forming conduction blocks
US93455267 Jul 201124 May 2016Myoscience, Inc.Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US9370391 *25 Jul 200521 Jun 2016Plymouth Hospitals Nhs TrustCatheter, apparatus for creating a linear ablation and a method of ablating tissue
US961011218 Mar 20144 Abr 2017Myoscience, Inc.Cryogenic enhancement of joint function, alleviation of joint stiffness and/or alleviation of pain associated with osteoarthritis
US966880018 Mar 20146 Jun 2017Myoscience, Inc.Methods and systems for treatment of spasticity
US975055619 Abr 20165 Sep 2017Boston Scientific Scimed, Inc.Cryotreatment devices and methods of forming conduction blocks
US20070088247 *12 Dic 200619 Abr 2007Galil Medical Ltd.Apparatus and method for thermal ablation of uterine fibroids
US20070167938 *18 Dic 200619 Jul 2007Galil Medical Ltd.Multiple cryoprobe delivery apparatus
US20080045934 *20 Ago 200721 Feb 2008Galil Medical Ltd.Device and method for coordinated insertion of a plurality of cryoprobes
US20080051774 *20 Ago 200728 Feb 2008Galil Medical Ltd.Device and method for coordinated insertion of a plurality of cryoprobes
US20080051775 *22 Nov 200628 Feb 2008Evans David KMulti-modal analgesia delivery system ("MADS")
US20080051776 *20 Ago 200728 Feb 2008Galil Medical Ltd.Thin uninsulated cryoprobe and insulating probe introducer
US20080300586 *4 Ago 20084 Dic 2008Galil Medical Ltd.Apparatus and method for compressing a gas, and cryosurgery system and method utilizing same
US20090005769 *25 Jul 20051 Ene 2009Plymouth Hospitals Nhs TrustCatheter, Apparatus for Creating a Linear Ablation and a Method of Ablating Tissue
US20090171334 *6 Mar 20092 Jul 2009Myoscience, Inc.Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US20090292279 *25 Ene 200726 Nov 2009Galil Medical Ltd.Device and Method for Coordinated Insertion of a Plurality of Cryoprobes
US20090299420 *29 May 20093 Dic 2009Shuros Allan CMethod and apparatus for cryotherapy and pacing preconditioning
US20100268217 *23 May 200721 Oct 2010Emcision LimitedVessel sealing device and methods
US20130184696 *14 Ene 201318 Jul 2013Myoscience, Inc.Cryogenic Needle with Freeze Zone Regulation
EP1786345B1 *25 Jul 200524 Abr 2013Plymouth Hospitals NHS TrustApparatus for creating a linear ablation
WO2007135431A2 *23 May 200729 Nov 2007Emcision LimitedVessel sealing device and methods
WO2007135431A3 *23 May 200710 Ene 2008Emcision LtdVessel sealing device and methods
WO2008142686A2 *21 May 200827 Nov 2008Uc-Care Ltd.Ablation probe
WO2008142686A3 *21 May 20087 May 2009Yeshayahu SchatzbergerAblation probe
Clasificaciones
Clasificación de EE.UU.606/21, 606/23
Clasificación internacionalA61B18/02
Clasificación cooperativaA61B18/0218, A61B18/02, A61B2018/0212, A61B2018/0293, A61B2018/0262
Clasificación europeaA61B18/02
Eventos legales
FechaCódigoEventoDescripción
10 Abr 2003ASAssignment
Owner name: SCIMED LIFE SYSTEMS, INC., MINNESOTA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LAFONTAINE, DANIEL M.;REEL/FRAME:013982/0358
Effective date: 20030408
6 Nov 2006ASAssignment
Owner name: BOSTON SCIENTIFIC SCIMED, INC., MINNESOTA
Free format text: CHANGE OF NAME;ASSIGNOR:SCIMED LIFE SYSTEMS, INC.;REEL/FRAME:018505/0868
Effective date: 20050101
Owner name: BOSTON SCIENTIFIC SCIMED, INC.,MINNESOTA
Free format text: CHANGE OF NAME;ASSIGNOR:SCIMED LIFE SYSTEMS, INC.;REEL/FRAME:018505/0868
Effective date: 20050101